Serum autoantibodies positivity prevalence in patients with chronic HCV and impact on pegylated interferon and ribavirin treatment response

Liver International

Volumn 33, Issue 10, 2013, Pages 1504-1509

  Khairy, Marwa ^a   El Raziky, Maissa ^a   El Akel, Wafaa ^a   Abdelbary, Mohamed S ^a   Khatab, Hany ^a   El Kholy, Badawy ^a   Esmat, Gamal ^a   Mabrouk, Mahassen ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

ALT; ANA; AST; HCV; Histological activity; Treatment response

Indexed keywords

AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; PEGINTERFERON; RIBAVIRIN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; THYROID DISEASE; TREATMENT RESPONSE;

ALT; ANA; AST; HCV; HISTOLOGICAL ACTIVITY; TREATMENT RESPONSE;

ANTIBODIES, ANTINUCLEAR; CROSS-SECTIONAL STUDIES; EGYPT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HEPATITIS C; HUMANS; PREVALENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; TRANSAMINASES;

EID: 84885182487     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12227     Document Type: Article

References (29)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29: 74-81.
2. Feld J, Liang T. Hepatitis C-identifying patients with progressive liver injury. Hepatology 2006; 43: S194-206.
3. Toubi E, Gordon S, Kessel A, et al. Elevated serum B lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun 2006; 27: 134-9.
4. Zignego AL, Craxi A. Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis 2008; 12: 611-36.
5. Ramos-Casals M, Trejo O, Garcia-Carrasco M, et al. Triple association between HCV infection, systemic autoimmune diseases, and B cell lymphoma. J Rheumatol 2004; 31: 495-9.
6. Cojocaru M, Cojocaru I, Iacob S. HCV infection-related autoimmunity. Mædica J Clin Med 2007; 2: 230-6.
7. Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21: 613-9.
8. Bogdanos DP, Mieli-Vergani G, Vergani D. Virus, liver and autoimmunity. Dig Liver Dis 2000; 32: 440-6.
9. Lenzi M, Bellentani S, Saccoccio G, et al. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut 1999; 45: 435-41.
10. Peterson JR, Hsu FC, Simkin PA, et al. Effect of tumor necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62: 1078-82.
11. Parke FA, Revielle JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004; 51: 800-11.
12. Ramos-Casals M, Loustaud-Ratti V, De Vita S, et al. Sjogren's syndrome associated with hepatitis C virus: a multicenter analysis of 137 patients. Medicine (Baltimore) 2005; 84: 81-9.
13. Bianchi FB, Muratori P, Granito A, et al. Hepatitis C and autoreactivity. Dig Liver Dis 2007; 1: S22-4.
14. Craxì A, Pawlotsky J, Wedemeyer, H, et al. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
15. Chen CH, Lee1 CM, Chen1 CH, et al. Prevalence and clinical relevance of serum autoantibodies in patients with chronic hepatitis C. Chang Gung Med J 2010; 33: 258-64.
16. Bedossa P, Poynard T. For the Metavir cooperation study group: an algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.
17. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 1: 169-76.
18. Narciso-Schiavon JL, Freire FC, Suarez MM, et al. Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon? Eur J Gastroenterol Hepatol 2009; 21: 350-6.
19. Hwang SJ, Chu CW, Huang DF, et al. Genetic predispositions for the presence of cryoglobulinemia and serum autoantibodies in Chinese patients with chronic hepatitis C. Tissue Antigens 2002; 59: 31-7.
20. Cassani F, Cataleta M, Valentini P, et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997; 26: 561-6.
21. Hsieh MY, Dai CY, Lee LP, et al. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C. J Clin Pathol 2008; 61: 333-7.
22. Satoh M, Chan EK, Ho LA, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012; 64: 2319-27.
23. Yee LJ, Kelleher P, Goldin RD, et al. Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. J Viral Hepat 2004; 11: 459-64.
24. Whitacre C. Sex differences in autoimmune disease. Nat Immunol 2001; 2: 777-80.
25. Conrad B. Potential mechanisms of interferon-alpha induced autoimmunity. Autoimmunity 2003; 36: 519-23.
26. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-9.
27. Muratori P, Muratori L, Guidi M, et al. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. Clin Infect Dis 2005; 40: 501-7.
28. Hsieh MY, Dai CY, Lee LP, et al. Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients. Kaohsiung J Med Sci 2012; 28: 86-93.
29. El-Zanaty F, Way A. Knowledge and Prevalence of Hepatitis C. Egypt Demographic and Health Survey, 2008; 241-58.